Zylox-Tonbridge Medical Technology Co., Ltd. disclosed that on 24 March 2026 it repurchased 28,500 H shares on the Hong Kong Stock Exchange at prices ranging from HK$22.86 to HK$23.50, spending a total of HK$0.67 million.

Following the transaction, the company’s issued shares (excluding treasury shares) decreased to 329.23 million, while treasury shares rose to 7.13 million. Total outstanding shares remained unchanged at 336.35 million. The latest buy-back equates to 0.0085 % of the company’s issued share capital prior to the repurchase.

The repurchase forms part of a mandate approved on 30 May 2025 that authorises the company to buy back up to 31.96 million shares. Including the latest transaction, Zylox-Tonbridge has repurchased 4.31 million shares under this mandate, representing 1.32 % of the share count at the mandate date.

In line with Hong Kong listing rules, a moratorium on new share issues or sales of treasury shares is in effect until 23 April 2026. The company confirmed that the repurchase complied with all applicable regulations and that all required funds have been fully settled.